Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Revenue

Target Prices

# of Analysts

Consensus Recommendation

EBITDA

EBIT

Free Cash Flow

FFO / Share

AFFO / Share

NAV / Share

Book Value / Share

CapEx

Estimates	Dec '22 (A)	Dec '23 (A)	Dec '24 (E)
Mean	DKK 175,090.13	DKK 228,919.75	DKK 290,081.48
Median	DKK 176,263	DKK 228,569.26	DKK 290,307.32
Actual	DKK 176,954	DKK 232,261	—
High	DKK 177,554	DKK 232,775.37	DKK 298,454.04
Low	DKK 155,610	DKK 225,177	DKK 281,100
Standard Deviation	DKK 4,288.05	DKK 2,288.63	DKK 3,767
# of Estimates	23	23	26

Novo Nordisk A/S

Long Term Revisions Restricted